TrialInternational journal of hematology2020

Elotuzumab plus lenalidomide and dexamethasone for newly diagnosed multiple myeloma: a randomized, open-label, phase 2 study in Japan.

Kohmei Kubo et al.PubMed ↗Publisher ↗

No numbers read from the abstract.